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Abstract
Background: Nitric oxide (NO) production following bacterial infection may play a physiological role in
the host defense mechanism due to its antimicrobial activity. However, excess production of NO in
severe infection such as sepsis has been implicated in the pathogenesis of septic shock. To determine
whether a nitronyl nitroxide NO scavenger compound could prevent the hemodynamic and blood gas
alterations in sepsis, bacterial lipopolysaccharide (LPS: 250ng/kg/min) was administered for 2 h in
anesthetized dogs with or without infusion of carboxy-2-phenyl-4, 4, 5, 5-tetramethylimidazoline-1-oxyl-
3-oxide (carboxy-PTIO: 0.1 mg/kg/min) for 1 h. Control animals received isotonic saline instead of LPS
with or without carboxy-PTIO.
Results: Infusion of LPS caused a marked decrease in mean arterial pressure (MAP), metabolic
acidosis, and hypoxia. These effects were reversed by co-administration of carboxy-PTIO, without
affecting other hemodynamic parameters. In control animals, neither hemodynamic nor blood gas
parameters changed with or without carboxy-PTIO.
Conclusion: These results indicate that carboxy-PTIO attenuates LPS-induced hypotension, metabolic
acidosis, and hypoxia by scavenging excess NO from the circulation without affecting NO synthase
(NOS) activity. An NO scavenger, carboxy-PTIO, may be preferable to non-selective NOS inhibitors for
the treatment of human septic shock.
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Introduction
Nitric oxide production by activated macrophages following
infection may play a physiological role in the host defense
mechanism due to its antimicrobial activity [1,2]. However,
sustained and excessive production of NO in severe infec-
tion such as sepsis has been implicated in the pathogene-
sis of septic shock [3–5]. Septic shock is characterized by
a hyperdynamic state (hypotension, tachycardia, normal or
increased cardiac output associated with low systemic vas-
cular resistance), an impairment of tissue perfusion, and
hyporesponsiveness to vasoconstrictors [6]. Nitric oxide is
produced by three distinct isoenzymes termed NO syn-
thases (NOS): brain and endothelial constitutive NOS
(cNOS), and inducible NOS (iNOS). Nitric oxide synthe-
sized by endothelial cNOS is involved in the regulation of
basal vascular tone and anti-thrombotic effect by inhibiting
platelet aggregation and leukocyte adhesion to the
endothelial surface [1]. Excess production of NO by iNOS,
stimulated by bacterial lipopolysaccharide (LPS) and sev-
eral cytokines, may contribute to the cardiovascular dys-
function seen in septic shock [3–5].
Several strategies can be used to reduce NO activity dur-
ing septic shock. L-arginine analogues, such as NG-mono-
methyl-L-arginine (L-NMMA), NG-nitro-L-arginine (L-NNA),
and NG-nitro-L-arginine methyl ester (L-NAME), are non-
selective inhibitors for cNOS and iNOS [1,2]. Although
these analogues increase blood pressure in septic shock
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decreasing cardiac output, oxygen delivery and metabolic
acidosis [4,5,7], possibly due to the non-selective inhibition
of endothelial cNOS as well as iNOS. To circumvent these
deleterious effects by non-selective NOS inhibitors, rela-
tively selective inhibitors for iNOS, such as aminoguanidine
[8,9] and S-methylisothiourea [10], have been developed
and studied in septic shock models. Other investigators
have tested methylene blue, an inhibitor of soluble guan-
ylate cyclase, which blocks the NO-mediated formation of
cyclic guanosine monophosphate (cGMP), a second mes-
senger for vasorelaxation in patients with septic shock [11].
Recently, Akaike et al[12] have reported that a nitronyl
nitroxide compound, 2-phenyl-4, 4, 5, 5-tetramethylimida-
zoline-1-oxyl-3-oxide (PTIO) derivative, reacts with NO to
generate NO2 and 2-phenyl-4, 4, 5, 5-tetramethylimidazo-
line-1-oxyl (PTI) derivative in a stoichiometric manner. Car-
boxy-PTIO, a water soluble derivative, has been shown to
attenuate hypotension and renal dysfunction in LPS-treated
rat models [13]. However, few studies have dealt with the
detailed hemodynamic or metabolic effects of the novel NO
scavenger in a septic shock dog model. In order to assess
the therapeutic potential of carboxy-PTIO in human septic
shock, our study was designed to examine the effects of
carboxy-PTIO on hemodynamic and blood gas variables in
LPS-induced septic shock dogs.
Materials and methods
Surgical preparation
The study was approved by the Institutional Review Board
for the care of animal subjects, and the care and handling
of the animals was in accord with National Institutes of
Health guidelines. Twenty mongrel dogs, 12.6 ± 0.7 kg,
were studied. The dogs were anesthetized for intubation
with intravenous administration of pentobarbital (20 mg/
kg), and connected to a ventilator. The inspired oxygen frac-
tion was maintained at 0.3, and the ventilator rate and tidal
volume were adjusted to obtain a normal arterial pH ad
PCO2 using a pH/blood gas analyser (IL 1306A, Instru-
mentation Laboratory, Lexington, MA, USA). A catheter was
inserted into the femoral vein and Ringer lactate solution
(10 ml/kg/h) and pentobarbital (4 mg/kg/h) were adminis-
tered throughout the study period. A pulmonary artery cath-
eter (93A-141-7F, Baxter Healthcare Corp, Santa Ana, CA,
USA) was inserted through the jugular vein. Another cathe-
ter was cannulated into the femoral artery for continuous
measurement of systemic arterial pressure, and intermittent
arterial blood sampling. Heart rate was monitored by elec-
trocardiogram. After surgical preparation, the dogs were
allowed to stabilize for 1 h.
LPS protocol
The dogs were divided into two experimental groups: in the
LPS group (n = 7), LPS (0127:B8, Difco Detroit, MI, USA)
was infused intravenously at a rate of 250 ng/kg/min for 2
h, as previously described [14]. In the LPS plus carboxy-
PTIO group (n = 7), 30 min after the start of LPS adminis-
tration (250 ng/kg/min, for 2 h), carboxy-PTIO (Dojindo
Laboratories, Kumamoto, Japan) was infused at a rate of
0.1 mg/kg/min for 1 h.
Sham protocol
In sham-shocked dogs, isotonic saline instead of LPS was
infused for 2 h without (sham-vehicle group n = 3) and with
carboxy-PTIO (sham-carboxy-PTIO group, n = 3) for 1 h.
Measurements of hemodynamic and blood gas 
parameters
Heart rate (HR), mean arterial pressure (MAP), mean pul-
monary arterial pressure (MPAP), pulmonary capillary
wedge pressure (PCWP), and central venous pressure
(CVP), were measured at baseline, 0.5, 1, 2, 3, and 4 h.
Cardiac output was simultaneously measured at baseline,
1,2,3, and 4 h using the thermodilution technique with a
cardiac output computer (9520A, Baxter Healthcare Corp,
Santa Ana, CA, USA); the mean value of two measure-
ments and the cardiac index (CI) were both calculated.
Arterial and mixed venous blood gases were measured at
baseline, 1, 2, 3, and 4 h. Systemic vascular resistance
index (SVRI), pulmonary vascular resistance index (PVRI),
oxygen delivery index (DO2I), and oxygen consumption
index (VO2I) were calculated using standard formulae.
Statistical analysis
All data are presented as mean ± SEM. Parameters were
compared over the study period using an analysis of vari-
ance for repeated measures. Where the F values was found
to be significant, the data were compared with Turkey's
test. Comparisons between the two groups at the same
time point were analysed by one-way analysis of variance
followed by Turkey's post hoc test when appropriate. P <
0.05 was considered statistically significant.
Results
Changes in hemodynamic parameters
In both the sham-vehicle group and the sham-carboxy-PTIO
group, no significant hemodynamic changes occurred dur-
ing the 4 h period (Fig 1a, and Table 1). In contrast, LPS
administration caused a significant (P < 0.01) decrease in
MAP during the 1-4 h period, and carboxy-PTIO reversed
the LPS-induced hypotension (Fig 1b). After LPS adminis-
tration, CI tended to decrease although not to a statistically
significant degree, and SVRI did not change during the 4 h
period (Fig 1b). Other hemodynamic parameters (PVRI,
MPAP, PCWP, CVP) did not change during the 4 h period
(Table 2).
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In both the sham-vehicle and the sham-carboxy-PTIO
group, no appreciable changes in blood gas parameters
(pH, PaO2, HCO3-, base excess) were observed during the
4 h period (Fig 2a). However, LPS administration caused
metabolic acidosis and hypoxia, effects which were
reversed by carboxy-PTIO (Fig 2b).
Discussion
This study clearly demonstrates that infusion of carboxy-
PTIO prevents LPS-induced hypotension as well as
metabolic acidosis and hypoxia in an endotoxin shock dog
model. In the present study, LPS caused a rapid (within 1
h) and sustained fall in MAP over a 4 h period. This early
decrease in MAP may be partly caused by immediate NO
release due to activation of endothelial cNOS. In fact, in a
study by Szabó et al, LPS-treated rats experienced early
(within 1 h) hypotension which was prevented by L-NAME,
but early hyporeactivity to noradrenaline was not inhibited
by dexamethasone, which blocks the induction of iNOS
[15], suggesting that the early hypotension is probably due
to NO generated by the activation of cNOS. The same
group has further suggested that the early NO-related vas-
cular changes may be associated with the formation of per-
oxynitrite from endothelial cNOS-derived NO and
superoxide [16]. Taken together, the mechanism of LPS-
induced hypotension is more likely due to NO-induced
peripheral vasodilation and vascular injury by peroxynitrite.
In our study, LPS-induced hypotension was accompanied
by a tendency towards decreased CI during the 4 h period,
suggesting that cardiac dysfunction may be a contributing
factor. As a result, the calculated SVRI did not decrease
despite peripheral vasodilation. The cause of this phenom-
enon may be explained by the method of fluid resuscitation
chosen for this study. Although 10 ml/kg/h crystalloid solu-
tion was administered during the study period, this fluid
resuscitation might not be sufficient to produce high car-
diac output as usually observed during human septic
shock.
Figure 1
Changes in mean arterial pressure (MAP), cardiac index (CI), and sys-
temic vascular resistance index (SVRI) in anesthetized dogs after 2 h 
intravenous administration of (a) isotonic saline or (b) bacterial lipopol-
ysaccharide (LPS: 250 ng/kg/min) with or without 1 h infusion of car-
boxy-PTIO (0.1 mg/kg/min). Each point represents the mean of sham-
vehicle group (n = 3), sham-carboxy-PTIO group (n = 3), LPS group (n 
= 7), and LPS plus carboxy-PTIO group (n = 7); bar shows SEM. *P < 
0.05, **P < 0.01 vs baseline value. †P < 0.05; difference between the 
two groups at the same time point.
Figure 2
Changes in arterial pH, PaO2, HCO3-, and base excess in anesthetized 
dogs after 2 h intravenous administration of (a) isotonic saline or (b) 
bacterial lipopolysaccharide (LPS: 250 ng/kg/min) with or without 1 h 
infusion or carboxy-PTIO (0.1 mg/kg/min). Each point represents the 
mean of sham-vehicle group (n = 3), sham-carboxy-PTIO group (n = 3), 
LPS group (n = 7), and LPS plus carboxy-PTIO group (n = 7); bar 
shows SEM. *P < 0.05, **P < 0.01 vs baseline value.Page 3 of 6
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NOS activity [17]. Therefore, the antihypotensive action of
carboxy-PTIO is most likely mediated through its reaction
with NO [12] to eliminate excess NO in septic shock animal
models. It has previously been reported that infusion of car-
boxy-PTIO (0.056–1.7 mg/kg/min for 1 h) into LPS-
induced septic shock rats dose-despondently prevented
the decrease in MAP and improved survival rate [13].
Therefore, we chose a lower carboxy-PTIO dose (0.1 mg/
kg/min for 1 h) for our dog model. Although blood carboxy-
PTIO levels gradually decrease after discontinuing infusion
[13], the LPS-induced hypotension was completely pre-
Table 1
Hemodynamic and gas exchange parameters in anesthetized dogs after isotonic saline infusion with or without carboxy-PTIO
Hours
Parameters Treatment 0 0.5 1 2 3 4
HR (beats/min) Saline 145 ± 18 135 ± 18 128 ± 23 133 ± 18 143 ± 13 152 ± 15
Carboxy-PTIO 152 ± 14 153 ± 14 150 ± 11 157 ± 11 151 ± 8 155 ± 9
MPAP (mmHg) Saline 15  ± 2 15 ± 2 15 ± 2 15 ± 2 16 ± 1 16 ± 0
Carboxy-PTIO 16 ± 2 16 ± 1 15 ± 1 15 ± 1 16 ± 2 17 ± 2
PCWP (mmHg) Saline 7 ± 2 7 ± 2 6 ± 2 8 ± 3 7 ± 3 5 ± 1
Carboxy-PTIO 7 ± 1 7 ± 1 7 ± 1 8 ± 1 8 ± 1 8 ± 1
CVP (mmHg) Saline 4± 1 5 ± 0 5 ± 1 4 ± 1 4 ± 1 5 ± 0
Carboxy-PTIO 5 ± 1 5 ± 1 5 ± 1 5 ± 1 5 ± 1 5 ± 1
PVRI (dyn s/
cm5m2)
Saline 168 ± 5 - 176 ± 32 186 ± 27 214 ± 51 225 ± 57
Carboxy-PTIO 163 ± 10 - 164 ± 21 168 ± 17 175 ± 31 199 ± 31
DO2I (ml min/m2) Saline 701 ± 91 - 636 ± 122 608 ± 108 633 ± 103 632 ± 85
Carboxy-PTIO 705 ± 97 - 647 ± 78 535 ± 26 553 ± 12 575 ± 30
VO2I (ml min/m2) Saline 112 ± 7 - 116 ± 6 118 ± 11 121 ± 10 123 ± 9
Carboxy-PTIO 103 ± 8 - 114 ± 14 120 ± 3 132 ± 7 137 ± 8
Values are mean ± SEM (n = 3). HR=heart rate; MPAP = mean pulmonary arterial pressure; PCWP = pulmonary capillary wedge pressure; CVP = 
central venous pressure; PVRI = pulmonary vascular resistance index; DO2I = O2 delivery index; VO2I, = O2 consumption index;- = not measured.
Table 2
Hemodynamic and gas exchange parameters in anesthetized dogs after intravenous administration of bacterial lipopolysaccharide with or 
without carboxy-PTIO
Hours
Parameters Treatment 0 0.5 1 2 3 4
HR (beats/min) LPS 143 ± 18 144 ± 8 150 ± 11 152 ± 6 157 ± 8 155 ± 10
Carboxy-PTIO 144 ± 13 147 ± 12 154 ± 12 156 ± 11 155 ± 11 158 ± 12
MPAP (mmHg) LPS 17 ± 13 17 ± 13 16 ± 13 18 ± 4 18 ± 4 19 ± 5
Carboxy-PTIO 16 ± 1 16 ± 1 16 ± 1 17 ± 1 17 ± 1 17 ± 1
PCWP (mmHg) LPS 8 ± 2 7 ± 1 7 ± 2 7 ± 2 7 ± 2 8 ± 2
Carboxy-PTIO 8 ± 1 8 ± 1 8 ± 1 8 ± 1 9 ± 1 9 ± 1
CVP (mmHg) LPS 4 ± 1 4 ± 1 3 ± 1 3 ± 1 4 ± 1 5 ± 1
Carboxy-PTIO 4 ± 1 3 ± 1 4 ± 1 4 ± 1 5 ± 1 4 ± 1
PVRI (dyn s/
cm5m2)
LPS 180 ± 22 - 201 ± 17 270 ± 34 229 ± 35 252 ± 51
Carboxy-PTIO 157 ± 13 - 168 ± 11 177 ± 17 208 ± 17 229 ± 27
DO2I (ml min/m2) LPS 592 ± 59 - 538 ± 49 438 ± 43 482 ± 44 439 ± 35
Carboxy-PTIO 722 ± 83 - 725 ± 65 679 ± 64 616 ± 58 558 ± 50
VO2I (ml min/m2) LPS 128 ± 17 - 115 ± 12 117 ± 14 127 ± 18 124 ± 12
Carboxy-PTIO 125 ± 12 - 123 ± 12 120 ± 13 123 ± 16 130 ± 17
Values are mean ± SEM (n = 7). LPS = lipopolysaccharide; HR = heart rate; MPAP = mean pulmonary arterial pressure; PCWP = pulmonary 
capillary wedge pressure; CVP = central venous pressure; PVRI = pulmonary vascular resistance index; DO2I = O2 delivery index; VO2I = O2 
consumption index;- = not measured.
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study. Thus, continuous infusion of carboxy-PTIO for 1 h
seems enough to maintain the plasma at a level high
enough to scavenge excess NO in the circulation.
Administration of carboxy-PTIO did not increase SVRI or
decrease CI during the 4 h period in our septic shock dog
model. These findings are in contrast to a marked decrease
in CI associated with peripheral vasoconstriction by non-
selective NOS inhibitors, such as L-NMMA, L-NNA, and L-
NAME [6,18,19]. It has been demonstrated that L-NMMA
caused a reduction in coronary flow associated with a
decrease in cardiac output in isolated rat hearts, possibly
as a result of myocardial ischemia [20]. By contrast, it has
recently been reported that carboxy-PTI, a reaction product
of carboxy-PTIO and NO, has a potent vasodilator effect in
the canine coronary artery without altering systemic hemo-
dynamic variables [21]. This effect may be responsible for
the maintenance of cardiac output following carboxy-PTIO
administration, and may also contribute to the maintenance
adequate regional blood flow.
It has been shown that the hemodynamic effect of carboxy-
PTIO is minimal in normal rats [13]. This finding was con-
firmed in our control dogs. This is in marked contrast to the
potent peripheral vasoconstriction by non-selective NOS
inhibitors [5,7]. The marked increase in systemic blood
pressure brought about by well known NOS inhibitors,
such as L-NMMA and L-NNA, is due to the complete inhi-
bition of endothelial cNOS. Since NO generated by
endothelial cNOS plays vital roles in maintaining organ
blood flow due to its vasodilator and antiplatelet aggrega-
tion effects, the complete blockade of endothelial cNOS by
non-selective NOS inhibitors during septic shock should
lead to a marked decrease in organ blood flow and
ischemia.
Administration of non-selective NOS inhibitors in septic
shock models has been shown to deteriorate metabolic
acidosis [7], reduce liver perfusion and induce liver injury
[5,22]. In contrast, a recent study from our laboratory has
revealed that in LPS-treated rabbits carboxy-PTIO pre-
served liver energetics, alleviated hepatocellular acidosis,
normalized various hydrophilic metabolites such as lactate
and alanine in the liver, and decreased plasma concentra-
tions of lactate and pyruvate [23]. These findings suggest
that carboxy-PTIO improves hepatocellular metabolic
derangement in endotoxin shock models. In this study car-
boxy-PTIO prevented LPS-induced metabolic acidosis and
hypoxia in a dog model, although lactate and hepatic
transaminases were not determined. It seems most likely
that the marked improvement in metabolic acidosis and
hypoxia in septic shock is due to the maintenance of ade-
quate organ perfusion and oxygen delivery by carboxy-
PTIO.
However, a major drawback of carboxy-PTIO for its poten-
tial use in septic shock is its inactivation by endogenous
reducing substances. For example, ascorbic acid has been
shown to reduce carboxy-PTIO to a non-radical N-hydroxy
derivative, which can no longer scavenge NO [13]. To over-
come such fast reduction of nitronyl-nitroxyl radicals,
attempts have been made to incorporate nitronyl nitroxide
into unilamellar phosphatidylcholine liposomes [24].
It should be noted that hemoglobin may also be used in
septic shock models and is as effective an NO scavenger
as carboxy-PTIO. It has recently been shown that adminis-
tration of cross-linked human hemoglobin in a septic pig
model improved MAP, but exacerbated pulmonary hyper-
tension and hypoxia [25]. Furthermore, it has been reported
that administration of stroma-free soluble hemoglobin
worsened hypoxia and acidosis in a septic dog model [26].
Therefore, the therapeutic potential of hemoglobin as an
NO scavenger in patients with sepsis appears to be more
limited than that of carboxy-PTIO.
In conclusion, our results show that carboxy-PTIO improves
blood pressure, metabolic acidosis, and hypoxia in septic
shock dogs through scavenging excess NO induced by
LPS. Since such NO scavengers preferentially quench the
biological action of excess NO without affecting NOS
activity, they may represent a promising approach to the
treatment of human septic shock. Further studies are
needed to design and develop more potent and long-lived
nitronyl nitroxide compounds.
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